Concepedia

Brett Wegner

BW

Statistics

Publications

4

Citations

97

H-Index

4

Active since

2005

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

The University of Texas MD Anderson Cancer Center

Brett Wegner is an author at Memorial Sloan Kettering Cancer Center specializing in phase ii investigation, lymphoma chemotherapy, and chemotherapy.

Publications per year

2005–2014

4

Publications

4

Phase I/<scp>II</scp> trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B‐cell lymphoma not eligible for autologous stem cell transplantation

David J. Straus, Paul A. Hamlin, Matthew J. Matasar et al. · British Journal of Haematology · 2014 · 31 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma

David J. Straus, Madeleine Duvic, Sarah McCue Horwitz et al. · Annals of Oncology · 2013 · 29 citations · Full text

Medicine, Oncology, Pharmacology +15

Early Safety and Efficacy Analysis of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) for Elderly High Risk Patients with Untreated DLBCL.

Paul A. Hamlin, Craig H. Moskowitz, Brett Wegner et al. · Blood · 2005 · 22 citations

Pharmacy, Geriatric Medicine, Pharmacotherapy +6

Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).

Paul A. Hamlin, Maria Alma Rodriguez, Ariela Noy et al. · Blood · 2010 · 15 citations

Medicine, Hematology, Oncology +15

1–4 of 4